All In Biotech

Drug Trial Radar · NCT04374877

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

145

Actual

Start

Apr 22, 2020

Primary completion

May 28, 2025

Study completion Jun 5, 2025

Sponsor

Lead sponsor
Coherus Oncology, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.

Conditions

  • Advanced Solid Tumor
  • Clear Cell Renal Cell Carcinoma
  • Hepatocellular Carcinoma
  • Non-small Cell Lung Cancer

Interventions

  • CHS-388Drug

    CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.

  • PembrolizumabDrug

    Pembrolizumab by intravenous (IV) infusion

  • ToripalimabDrug

    Toripalimab by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Part A] Dose Limiting Toxicity (DLT)Time frame: Assessed during first 28 days of treatment
  2. [Part B] Confirmed objective response rate (ORR)Time frame: Up to 24 months
  3. [Part C] DLTTime frame: Assessed during first 21 days of treatment
  4. [Part C] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)Time frame: Up to 24 months
  5. [Part C -NSCLC Cohort] Objective response rate (ORR)Time frame: Up to 24 months
  6. [Part D] Objective response rate (ORR)Time frame: Up to 24 months

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of Southern California (USC) - Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • University of Miami Leonard M. Miller School of Medicine (UMMSM)

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System (UMHS)

    Ann Arbor, Michigan

  • Washington University School of Medicine - St. Louis

    St Louis, Missouri

  • Roswell Park

    Buffalo, New York

  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI))

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center (VUMC)

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

  • University of Washington

    Seattle, Washington

  • National University Hospital

    Singapore, Singapore

  • National Cancer Center Singapore (NCCS)

    Singapore, Singapore

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.